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Do mixed histological features affect survival 
benefit from neoadjuvant platinum-based 
combination chemotherapy in patients with 
locally advanced bladder cancer? A secondary 
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and for patients with mixed tumours, with 




• There was evidence of a survival benefit 
from chemotherapy in patients with mixed 









 0.02). Patients with pure UC had 
improved survival on the chemotherapy arm 
but the survival benefit was not statistically 










• There was marginal evidence that the 
survival benefit of chemotherapy in patients 
with mixed tumours was greater than it was 












• Presence of squamous or glandular 
differentiation in locally advanced UC of the 
bladder does not confer resistance to MVAC 
and in fact may be an indication for the use 





urothelial carcinoma, mixed histological 
features, neoadjuvant chemotherapy
 
What’s known on the subject? and What does the study add?
 
In a meta-analysis of randomized trials, neoadjuvant platinum-based combination 
chemotherapy administered before definitive local treatment improved survival of 
patients with muscle-invasive bladder cancer compared with definitive local treatment 
alone. However, it was not known whether chemotherapy was equally effective for pure 
urothelial carcinoma versus urothelial carcinoma with mixed histological features, such as 
squamous or glandular differentiation.
To address this question we performed a secondary analysis of the Southwest Oncology 
Group-directed intergroup randomized trial S8710 of neoadjuvant methotrexate, 
vinblastine, doxorubicin, and cisplatin (MVAC) followed by cystectomy versus cystectomy 
alone for treatment of locally advanced urothelial cancer of the bladder. Our findings 
suggest that presence of squamous or glandular differentiation does not confer 
resistance to combination chemotherapy with MVAC and in fact may be an indication for 
the use of neoadjuvant chemotherapy before radical cystectomy.
Study Type – Therapy (RCT)




• To determine whether the effect of 
neoadjuvant chemotherapy with 
methotrexate, vinblastine, doxorubicin and 
cisplatin (MVAC) on the survival of patients 
with locally advanced urothelial carcinoma 
(UC) of the bladder treated with radical 
cystectomy varies with the presence of non-




• This is a secondary analysis of the 
Southwest Oncology Group-directed 
intergroup randomized trial S8710 of 
neoadjuvant MVAC followed by cystectomy 
versus cystectomy alone for treatment of 
locally advanced UC of the bladder.
• For the purpose of these analyses, 
tumours were classified based on the 
presence of non-urothelial components as 
















 59). Non-urothelial components included 
squamous and glandular differentiation.
• Cox regression models were used to 
estimate the effect of neoadjuvant MVAC on 
all-cause mortality for patients with pure UC 
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Bladder cancer (BC) is the fifth most 
commonly diagnosed malignancy in the USA, 
with more than 70 000 new cases and more 
than 14 000 deaths reported in 2009 [1,2]. 
Most deaths from BC occur among patients 
with an initial diagnosis of muscle-invasive 
disease (stages T2–T4). Standard therapy for 
resectable (T2–T4a) muscle-invasive BC 
without known metastases includes radical 
cystectomy with pelvic lymphadenectomy [3]. 
Unfortunately, many patients with apparently 
resectable muscle-invasive BC have 
undiagnosed micrometastatic disease at the 
time of definitive surgery. In a series of 1054 
patients treated with radical cystectomy and 
pelvic lymphadenectomy between 1977 and 
1997, with a median follow up of 10.2 years, 
BC recurred in 311 patients (30%) with a 
median time to recurrence of 12 months. 
Three-quarters of all patients with disease 
recurrence had distant metastases [4].
Early treatment of micrometastatic disease 
with neoadjuvant platinum-based 
combination chemotherapy (PBCC) 
administered before definitive local treatment 
(cystectomy and/or radiotherapy) has been 
compared with local treatment alone in 
several randomized trials. A meta-analysis of 
these trials showed that addition of a neo-
adjuvant PBCC regimen to local treatment 
improves the average 5-year survival by 5% 
on the additive scale (from 45% to 50%) [5]. 
Several trials also reported that the use of 
neoadjuvant PBCC may increase the 
probability of pathological stage zero (pT0) at 
cystectomy from approximately 12–15% in 
the cystectomy-only arm to 33–38% in the 
PBCC plus cystectomy arm [6,7].
Although most patients who are treated with 
radical cystectomy for muscle-invasive BC 
have pure urothelial carcinoma (UC), tumours 
with mixed histological features (UC co-
existing with non-urothelial histology) are 
also common. For example, in a series of 243 
patients with clinical stage of at least T2, 96 
patients (40%) had mixed histological 
features, most frequently UC with squamous 
and/or glandular differentiation [8].
It is currently unknown whether the benefit of 
neoadjuvant PBCC on pathological down-
staging and survival of patients with 
apparently resectable muscle-invasive UC 
treated with radical cystectomy is influenced 
by the presence of a non-urothelial 
component in the tumour. Observational 
studies suggested that among patients with 
metastatic BC, patients with pure UC as well 
as patients with mixed tumours can achieve a 
complete clinical response to PBCC 
(disappearance of all clinical and radiographic 
evidence of disease) [9,10]. In one series of 
patients with metastatic BC, complete clinical 
response to PBCC was reported in 39% of 74 
patients with pure UC and in 25% of 20 
patients with mixed histology (UC with 
squamous, glandular or spindle cell 
components) [9]. In another series of patients 
with metastatic UC, any clinical response to 
PBCC (complete or partial) was observed in 
44% of 389 patients with pure UC and in 34% 
of 42 patients with mixed urothelial and 
squamous histology [10].
These findings reported for metastatic UC 
may not be directly applicable to patients with 
apparently resectable BC because the biology 
of metastatic and locally advanced tumours 
may be different. In particular, complete 
clinical response of metastatic lesions (which 
is determined primarily by imaging studies) 
may not be equivalent to complete 
pathological response of the primary tumour 
in the bladder (stage pT0 at cystectomy). In 
addition, survival of patients with metastatic 
BC is usually very poor. While histological type 
may not have a strong impact on survival of 
patients with this very advanced form of 
disease, it may theoretically influence both 
response to chemotherapy and survival of 
patients with less advanced tumours treated 
with cystectomy and neoadjuvant PBCC with 
curative intent.
The purpose of the current study is to 
determine whether the effect of neoadjuvant 
PBCC on pathological down-staging and 
survival of patients with locally advanced 
UC of the bladder treated with radical 
cystectomy was influenced by the presence of 




This is a secondary analysis of the 
Southwestern Oncology Group (SWOG) -
directed intergroup trial of neo-adjuvant 
methotrexate, vinblastine, doxorubicin, 
cisplatin (MVAC) followed by cystectomy 
versus cystectomy alone (SWOG 8710) [6]. 
Eligibility criteria for the trial included 
clinical stage T2–T4a N0 M0 UC of the 
bladder, no previous pelvic radiation, 
adequate renal, hepatic and haematological 
function, and a SWOG performance status of 
0 or 1 [6]. A total of 307 eligible patients 
were enrolled between 1987 and 1998 and 


















 154) (Fig. 1). According to the study 
protocol, two pathological reviews were 
planned for each patient: first, a central 
pathological review of the pre-registration 
biopsy (transurethral resection) specimen to 
confirm eligibility, and second, a review of 
the cystectomy specimen to determine the 
pathological stage. As was discussed in the 
original publication, the first review was not 
performed for 46 patients because slides 
were not submitted or were lost in shipment 
[6]. These patients were enrolled in the trial 
and underwent randomization. Of the 
remaining patients, four had missing 
information on histological type from the 
first review (because of inadequate specimen 





histological type was determined from the 
institutional pathology reports. For all other 
patients, histological type was determined by 
the central pathological review (performed 
by a single expert genitourinary pathologist 
per case).
For the purpose of analyses reported in this 
paper, tumours were classified based on the 
presence of non-urothelial components as 

















 61). For 10 patients, tumours could not be 
definitively classified as either pure or mixed 
based on available information. These 10 
patients were excluded from our analysis. 




































 2). The two patients with other 
histological types (one small cell and one 
signet ring) were also excluded to make the 
mixed histology group a more homogeneous 
pathological entity (UC with squamous and/or 
glandular differentiation). None of the 
tumours in this study had a documentation 
of micropapillary features. The relative 
frequencies of cases contributed by different 
study centres were similar for the two 
histology groups (pure UC and mixed 
tumours).
The primary covariates of interest in the 
current analyses were ‘treatment’ (MVAC 
plus cystectomy vs cystectomy alone) and 
‘histological type’ (pure UC vs mixed 
tumours). Other candidate covariates 
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included age at randomization (in years), 
clinical stage (T2 vs T3–T4a), gender (male or 
female), and race (white or other race). The 
clinical stages were defined according to the 
fourth edition of the American Joint 
Committee on Cancer staging manual [6,11]. 
Two outcome measures were examined in the 
current study: the probability of no residual 
tumour in the cystectomy specimen (stage 
pT0 at cystectomy), and the hazard of death 
from all causes (all-cause mortality). All-cause 
mortality was the primary endpoint of the 
trial according to the original study protocol. 
Survival time was measured from 
randomization until death from any cause. All 
patients provided written informed consent, 
and the study was approved by the ethics 
committees of participating institutions.
The proportions of patients with stage pT0 at 
cystectomy were compared between the two 
treatment arms separately for patients with 
pure UC and for patients with mixed tumours 
using the chi-squared test or the Fisher’s 
exact test (where appropriate). The same 
methods were used to compare the 
proportions of pT0s at cystectomy between 
patients with pure UC and patients with 
mixed tumours within each treatment arm. 
Direct standardization was used to adjust the 
estimated down-staging effects of treatment 
and histological type for clinical stage and to 
test for treatment-by-histological type 
interaction with stage-adjustment [12–14]. 
The statistical interaction between treatment 
and histological type would indicate that the 
effect of treatment in patients with mixed 
tumours is different in magnitude from the 
effect of treatment in patients with pure UC. 
In the analysis of tumour down-staging, we 
made a conservative assumption that patients 
who did not undergo cystectomy, regardless 
of reason, had residual disease (they were 
considered not to have stage pT0).
The effect of MVAC on all-cause mortality was 
estimated separately for patients with mixed 
tumours and for patients with pure UC using 
the Cox model [15]. This model was also used 
to estimate the effect of histological type 
(mixed tumours vs pure UC) on all-cause 
mortality within each treatment arm and to 
test for treatment-by-histological type 
interaction. All regression models were 
stratified on clinical stage and included age as 
a continuous covariate. Hence, the estimated 
effects of treatment and histological type on 
the hazard of death from all causes were 
controlled for age and clinical stage at 
randomization in all comparisons reported in 
this paper. The assumptions of proportional 
hazards and of linearity of age (the only 
continuous covariate) with respect to the log-
hazard were checked and no major model 
violations were observed. Product terms were 
used to test for treatment-by-histological 
type interaction. All analyses were performed 
in SAS version 9.2 (SAS Institute, Cary, NC, 








The distribution of patient characteristics 
for each combination of treatment and 
histological type is shown in Table 1. Table 2 
shows numbers and percentages of patients 
who had stage pT0 based on pathological 
examination of the cystectomy specimen and 
numbers and percentages of patients whose 
pT0 status was not known. The pT0 status was 









 243) or had surgery cancelled 
or aborted because of overt disease 
progression/unresectable disease. The pT0 
status was not known for 29 patients who did 
not undergo cystectomy for reasons other 
than overt disease progression (e.g. refused 
cystectomy for personal reasons).
The percentages of patients with stage pT0 in 
Table 2 were calculated by dividing the 
number of patients with pT0 by the total 
number of patients in the corresponding 
combination of treatment with histological 




CONSORT diagram for the SWOG 8710 trial: MVAC, methotrexate, vinblastine, doxorubicin, and 
cisplatin; UC, urothelial carcinoma.
Assessed for eligibility (n = 317)
Excluded (n = 10)
Not meeting inclusion criteria (n = 10)
Refused to participate (n = 0)
Other reasons (n = 0 )
Patients randomly assigned (n = 307)
Lost to follow up (n = 4)
Allocated to cystectomy alone (n = 154)
Received cystectomy (n = 124)
Did not receive cystectomy (n = 30)
Analysed (n = 148)
Excluded from analysis (n = 6)
Lost to follow up (n = 1)
Discontinued MVAC intervention (n = 15)
Analysed (n = 147)
Excluded from analysis (n = 6)
Allocated to combination therapy (n = 153)
Received MVAC and Cystectomy (n = 124)
Received MVAC but not Cystectomy (n = 24)
Received Cystectomy but not MVAC (n = 2)
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all patients whose pT0 status was not known 
had residual disease (did not have stage pT0). 
In the crude analysis, the additive down-
staging effect (ADE) of chemotherapy 
estimated with this conservative assumption 









0.004) for patients with mixed tumours, and 








 0.006) for 
patients with pure UC. The estimated ADE of 









 0.53) in the MVAC-plus-












 0.20) in the cystectomy-only arm.
The ADEs of treatment and histological type 
estimated with adjustment for clinical stage 
are shown in Table 3. These effects were very 
similar to the crude effects in terms of their 
magnitude and statistical significance. 
Evidence of tumour down-staging to pT0 
after chemotherapy was clearly present 













 0.004) and among patients with 





















Among patients with mixed tumours 
randomized to MVAC plus cystectomy, stage 
pT0 at the time of definitive surgery was 
observed in 6 of 20 patients with urothelial 
and squamous differentiation and in 5 of 10 
patients with urothelial and glandular 
differentiation. Hence, pathological down-
staging after chemotherapy was observed in 
both sub-types of mixed tumours, and was 
clearly not limited to only one sub-type 
(squamous or glandular).
Table 4 shows the estimated hazard ratios 
(HR) for the effect of MVAC on all-cause 
mortality among patients with mixed 
tumours (model 1) and among patients 
with pure UC (model 2). Also included in 
Table 4 are the estimated HR for the 
effect of mixed histology on all-cause 
mortality among patients randomized to 
MVAC-plus-cystectomy (model 3) and 
among patients randomized to cystectomy 
alone (model 4).
There was evidence of a survival benefit from 














0.02). Patients with pure UC had improved 
survival on the chemotherapy arm; however, 














0.48). There was marginal evidence that the 




Numbers and percentages of patients who had stage pT0 at cystectomy and numbers and 
percentages of patients whose pT0 status was not known, by treatment–histology combinations
 






No. (%) with pT0
status unknown




 cystectomy 32 11 (34) 4 (13)
Mixed tumours Cystectomy alone 27 1 (4) 3 (11)




 cystectomy 115 33 (29) 15 (13)
Pure UC Cystectomy alone 121 17 (14) 7 (6)
 



















1 Mixed tumours 59 MVAC vs cystectomy-only 28 (11–44) 0.004









11 to 23) 0.51








20 to 3) 0.27
 
*ADE, additive down-staging effect, directly standardized to the distribution of clinical stages among all 
patients included in the analysis. 95% CI, 95% confidence intervals; UC, urothelial carcinoma; MVAC, 

















1 Mixed tumours 59 MVAC vs cystectomy-only 0.46 (0.25–0.87) 0.02





 cystectomy 147 Mixed vs pure UC 0.69 (0.42–1.13) 0.14
4 Cystectomy-only 148 Mixed vs pure UC 1.28 (0.80–2.06) 0.30
 
HR, hazard ratio, adjusted for age and clinical stage; 95% CI, 95% confidence intervals; UC, urothelial 




Patient characteristics for each combination of treatment with histological type
 
Characteristic


















32 27 115 121
Mean age (years) 60 65 63 62
cT3–T4a*, % 59 70 59 57
Women, % 31 15 14 21
White, % 91 78 96 96
 
*cT3–T4a, clinical stage T3 or T4a. UC, urothelial carcinoma; MVAC, methotrexate, vinblastine, 
doxorubicin and cisplatin.
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with mixed tumours was greater than it 









 0.09). These analyses also 
suggested that compared with pure UC, mixed 
tumours may be associated with increased 
mortality when treated with cystectomy alone 
and with decreased mortality when treated 
with MVAC plus cystectomy, although the 
estimated HR were relatively imprecise in 
these two comparisons (rows 3 and 4 of 
Table 4). Table 5 shows the age-standardized 
5-year survival estimates by treatment, 
histological type and clinical stage obtained 
from the Cox model. The estimated 
improvement in 5-year survival associated 
with MVAC was much greater in magnitude 
among patients with mixed tumours than 
among patients with pure UC.
All estimates in Tables 4 and 5 were controlled 
for age and clinical stage. These covariates 
were pre-specified in the original study 
protocol as stratification factors for survival 
analysis. Because the covariates gender 
and race also appeared to be somewhat 
unbalanced between the comparison sub-
groups (Table 1), we performed sensitivity 
analyses by including these covariates 
in the model. Gender and race were not 
independently associated with all-cause 
mortality in these analyses (after adjusting for 
age, clinical stage and histological type) and 





The purpose of this study was to determine 
whether the effect of neoadjuvant MVAC on 
pathological down-staging and survival of 
patients with locally advanced UC of the 
bladder treated with radical cystectomy is 
influenced by the presence of squamous and/
or glandular components in the tumour. This 
question is important because squamous and/
or glandular differentiation co-existing with 
malignant urothelial histology is a fairly 
common finding in muscle-invasive BC. To 
our knowledge, it has never been clearly 
showed that neoadjuvant PBCC can induce 
complete pathological response (stage pT0) 
and improve survival of patients with these 
mixed tumours. Before results of the current 
analyses became available, we considered it 
possible that the presence of non-urothelial 
components could render UC resistant to 
MVAC. If this was confirmed, then patients 
with mixed tumours could potentially benefit 
from immediate cystectomy (without 
neoadjuvant chemotherapy), especially as 
delaying cystectomy for more than 3 months 
from diagnosis of muscle invasion has been 
associated with decreased survival in some 
patient populations [16].
Our current analyses have showed that the 
presence of squamous and/or glandular 
differentiation does not make a locally 
advanced UC of the bladder resistant to 
neoadjuvant chemotherapy with MVAC. 
Evidence of tumour down-staging to pT0 
after chemotherapy was clearly present 

























 0.004) (Table 3). The 
actual proportions of pT0s reported in these 
analyses for each combination of treatment 
with histological type (Table 2) are slightly 
less than the proportions originally reported 
for all histological types combined (15% in 
the cystectomy-only arm and 38% in the 
MVAC-plus-cystectomy arm) [6]. In the 
original analyses, the proportions of pT0s 
were computed using only those patients who 
received cystectomy. Because some patients 
did not undergo cystectomy because of 
disease progression/unresectable disease and 
others refused surgery or did not receive it for 
unknown reasons, in the current analyses 
of tumour down-staging we made a 
conservative assumption that patients who 
did not undergo cystectomy, regardless of 
reason, had residual disease (they were 
considered not to have stage pT0). This is the 
most conservative approach to the analysis of 
tumour down-staging. Indeed, it is possible 
that some patients who refused cystectomy 
did so because of complete clinical response 
to chemotherapy. If some of these patients in 
fact had no residual disease, then the down-
staging effect of chemotherapy reported in 
this paper could be underestimated. This 
down-staging effect (estimated under the 
most conservative assumptions) was 
nevertheless fairly large in magnitude, 
especially for patients with mixed tumours 
(28% on the additive scale or 28 extra pT0s 








 0.004). The 
estimated survival benefit of chemotherapy 
among patients with mixed tumours was also 












 0.02). For patients 
with pure UC, the estimated improvement in 














The strengths of this study include 
randomized treatment allocation, central 
pathological review (performed for most 
patients), the use of the standard treatment 
protocol (MVAC as the only form of 
neoadjuvant chemotherapy, no previous 
pelvic irradiation, etc.), and rigorous follow 
up. However, some limitations of this study 
exist. First, the results of the current 
analyses may be difficult or impossible to 
generalize to mixed urothelial tumours with 
non-urothelial components other than 
squamous cell or adenocarcinoma. For 
example, there is evidence to suggest that 
small cell tumours of the bladder may 
respond better to neuroendocrine regimens 
than to urothelial regimens such as MVAC 
[17]. Second, even for squamous and 
glandular components, survival could not be 
analysed separately in the current study 
because the estimated HR would be highly 
imprecise because of the small sample size 
for individual histological sub-types. 
However, our analyses suggested that 
pathological down-staging after 
chemotherapy occurs in both sub-types of 
mixed tumours (squamous and glandular), 
and clearly is not limited to only one sub-
type. Hence, it is unlikely that improvement 
in survival after chemotherapy is limited to 




Estimated five-year survival probabilities
 
Stage Treatment
Pure UC Mixed Tumors
5-yr survival* 95% CI 5-yr survival* 95% CI
cT2 Cystectomy-only 0.61 (0.52, 0.72) 0.54 (0.39, 0.74)
cT2 MVAC 
 
+ cystectomy 0.64 (0.55, 0.74) 0.73 (0.62, 0.86)
cT3-T4a Cystectomy-only 0.42 (0.34, 0.53) 0.34 (0.21, 0.55)
cT3-T4a MVAC + cystectomy 0.46 (0.37, 0.56) 0.58 (0.45, 0.75)
*Adjusted for age by conditional standardization (conditioned on the average age of all patients in the 
study); cT2 = clinical stage T2, cT3-T4a = clinical stage T3-T4a. UC, urothelial carcinoma; MVAC, 
methotrexate, vinblastine, doxorubicin and cisplatin.
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It must also be recognized that definition 
and documentation of mixed histology may 
vary between pathologists. In our study, 
histological type of 50 patients was 
determined by institutional pathology report 
because slides were not available for the 
central review (these patients contributed 12 
of the 59 mixed histology cases). Hence some 
potential misclassification of histological 
types in our study could occur, and this must 
be recognized as a limitation. Similarly, 
proportions of non-urothelial components in 
mixed histology tumours could not be 
obtained from this analysis (it was rarely 
reported) and so the impact of this proportion 
on response to MVAC or outcome in the 
cystectomy-only arm could not be 
ascertained.
Another question which needs to be 
considered is whether results reported in this 
paper are fully applicable to PBCC regimens 
other than MVAC. In the setting of metastatic 
disease, MVAC seems to result in the same 
survival as a less toxic regimen composed of 
gemcitabine and cisplatin [18]. However, the 
two regimens have never been directly 
compared in the setting of apparently 
resectable BC. Hence, the ability of 
gemcitabine and cisplatin to induce complete 
pathological response and improve survival of 
patients with locally advanced UC of the 
bladder with non-urothelial components 
remains uncertain.
Some of the questions that could not be fully 
answered in this study may potentially be 
examined in secondary analyses of other 
trials of neoadjuvant PBCC for locally 
advanced BC, and possibly in pooled analyses 
of two or more trials. For example, a 
European trial of CMV (cisplatin, 
methotrexate and vinblastine) enrolled more 
than 900 patients with stage T2–T4a N0/NX 
M0 BC [7]. To our knowledge, the effect of 
CMV in that trial has not been examined 
separately for patients with pure UC and for 
patients with mixed tumours. A pooled 
analysis of two or more trials would improve 
statistical power and increase the precision 
of estimation. This would be particularly 
beneficial for the formal test of statistical 
interaction between treatment and 
histological type. Unfortunately, interaction 
effects are difficult to detect in studies 
powered for the analysis of the main effects 
[19]. Even large interactions often produce P 
values above α = 0.05 (the conventional level 
of significance for the main effects) in 
moderate-sized studies. Secondary analyses 
of larger trials and pooled analyses of two or 
more trials may be particularly beneficial in 
these situations.
In summary, presence of squamous or 
glandular differentiation in locally advanced 
UC of the bladder does not confer resistance 
to MVAC and in fact may be an indication for 
the use of neoadjuvant chemotherapy before 
radical cystectomy.
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EDITORIAL COMMENT
DO MIXED HISTOLOGICAL FEATURES 
AFFECT SURVIVAL BENEFIT FROM 
NEOADJUVANT PLATINUM-BASED 
COMBINATION CHEMOTHERAPY IN 
PATIENTS WITH LOCALLY ADVANCED 
BLADDER CANCER?
The S8710 trial of neoadjuvant 
chemotherapy with methotrexate, 
vinblastine, adriamycin and cisplatin 
(M-VAC) followed by cystectomy versus 
cystectomy alone established the role for 
neoadjuvant chemotherapy in patients with 
muscle-invasive bladder cancer [1]. This 
secondary analysis of S8710 sought to 
determine if the effect seen with 
neoadjuvant M-VAC varied with the 
presence of non-urothelial components in 
the tumor. The presence of mixed histology 
in bladder tumors has been associated with 
aggressive disease as well as more advanced 
disease at the time of presentation [2,3]. For 
the analysis, the authors looked at non-
urothelial components including squamous 
and/or glandular differentiation and used 
Cox regression models to estimate the 
effect of neoadjuvant chemotherapy on 
mortality for pure urothelial carcinoma (UC) 
patients and those with mixed tumors. 
There was an expectation that based on the 
previously reported aggressive nature of 
mixed tumors, the outcome for these 
patients would be inferior [4,5]. The analysis, 
however, demonstrated that patients with 
mixed histology tumors appear to derive 
a survival benefit from neoadjuvant 
chemotherapy (HR = 0.46; 95% CI: 
0.25–0.87; P = 0.02). Although intriguing, 
the interpretation of the results of this 
analysis is limited by several important 
issues. Most significant is the lack of 
central pathological review for 50 patient 
specimens where histologic type was 
determined from the institutional pathology 
reports (12 of the 59 mixed histology cases). 
Furthermore, the proportion of non-
urothelial component in these mixed 
histology tumors was rarely reported. 
Additionally, “mixed histology” was limited 
to squamous and glandular differentiation 
and thus the analysis cannot be extended to 
other histologic subtypes and the small 
number of mixed histology cases limits the 
ability to detect differences in survival for 
the individual histologic subtypes of 
squamous and glandular differentiation.
Ultimately, our understanding of bladder 
cancer biology must not be limited to 
histologic variants, but must incorporate the 
underlying genetic and molecular drivers of 
disease aggressiveness as well as markers of 
chemosensitivity. For example, DNA repair 
mechanisms such as the excision repair cross-
complementation group 1 (ERCC1) in non-
small cell lung cancer and microsatellite 
instability, a hallmark of the mismatch repair 
phenotype, in colon cancer may be used to 
predict for disease aggressiveness as well as 
for sensitivity to chemotherapy [6–8]. Host 
factors independent of tumor biology further 
confound our understanding of treatment 
response and outcome. As the role for 
pharmacogenomics such as single nucleotide 
polymorphisms that predict sensitivity to 
cisplatin are better understood, so too will our 
ability to tailor therapy to specific patients [9]. 
Ongoing studies to determine driver genetic 
alterations and pharmacogenomics that 
predict both response and resistance to 
therapy will undoubtedly lead to better 
treatment strategies and outcomes for our 
patients.
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